Replies to post #62050 on Biotech Values

[DewDiligence]

IDIX will present IDX899 phase-1/2
monotherapy data from all dosing cohorts at:

ESCMID – Mechanisms of Antimicrobial Resistance
June 15-21, 2008
Palma de Mallorca, Spain
http://www.escmid.org

Top-line data from the 800mg (highest) dose were disclosed in a PR on 2/6/08.